Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tongjitang Chinese Medicines Revenues Lower in Q2

publication date: Aug 15, 2008

Tongjitang Chinese Medicines Company had the unfortunate responsibility of informing investors that, once again, its revenues for the quarter were lower than the year-earlier period. Trying to put a good face on the news, Tongjitang led its announcement by saying that Q2 revenues were up 13% from Q1, a hopeful sign. Still, the unavoidable fact remains that its Q2 sales, which came in at $17.4 million, were down 15% from 2007’s second quarter. The company’s problem remains that competitors are selling counterfeit versions of its flagship product, the TCM osteoporosis treatment Xianling Gubao. More details...

Stock Symbol: (NYSE: TCM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital